Flash Finance

Shree Ganesh Biotech (India) Ltd539470Corporate

Biotechnology Latest results: Jun 2026 14 quarters of data
₹0.47
MCap ₹18 Cr
Shree Ganesh Biotech (India) Ltd — Stock analysis & AI research Shree Ganesh Biotech (India) Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹1 Cr
Sales · Jun 2026
+3.6% YoY
₹-1 Cr
Operating Profit · Jun 2026
-892.6% YoY
-62.5%
OPM % · Jun 2026
-861.5% YoY
₹-1 Cr
Net Profit · Jun 2026
-273.7% YoY
₹-0.01
EPS · Jun 2026
-200.0% YoY

📝 Shree Ganesh Biotech (India) Ltd — results explained

Quarter ended June 2026 (Q1 FY27)

Shree Ganesh Biotech (India) Ltd reported revenue of ₹1 crore for the quarter ended June 2026 (Q1 FY27), up 3.6% from ₹1 crore in the same quarter last year, and down 32.6% sequentially over the March 2026 quarter.

The company reported a net loss of ₹1 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.01.

Operating profit stood at ₹-1 crore — an operating margin (OPM) of -62.5%, compared with -6.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Shree Ganesh Biotech (India) Ltd posted revenue of ₹5 crore, a decline of 78.4% over FY25, with a net profit of ₹1 crore (up 34.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹5 crore with a net loss of ₹0 crore.

Valuation snapshot

At the current price of ₹0.47, 539470 has a market capitalisation of ₹18 crore.

Within the Biotechnology industry, it is the 7th-largest of the 8 companies we track by market value.

Shareholding pattern

As of Jun 2026, foreign institutional investors (FIIs) 1.42%, public shareholders 98.59% of Shree Ganesh Biotech (India) Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹18 Cr
Current Price ?
₹0.5
P/E ?
N/A
Industry P/E ?
106.70
P/B ?
0.29
P/S ?
3.65
P/FCF ?
-2.24
Enterprise Value ?
₹18 Cr
EV/EBITDA ?
-10.34
PEG ?
N/A
Earnings Yield ?
-9.7%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹5 Cr
OPM ?
-35.3%
Profit after tax (TTM) ?
₹-0 Cr
EPS (TTM) ?
₹-0.01
ROCE ?
0.8%
ROE ?
-0.6%
ROA ?
-0.6%
Growth
Sales — latest qtr ?
₹1 Cr
PAT — latest qtr ?
₹-1 Cr
YoY qtr sales growth ?
3.6%
YoY qtr profit growth ?
-273.7%
Sales growth (3y) ?
-57%
Sales growth (5y) ?
-22%
Profit growth (3y) ?
-43%
Profit growth (5y) ?
-6%
Financial Health
Debt ?
₹0 Cr
Debt to Equity ?
0.00
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
N/A
Change in promoter holding ?
N/A
Pledged percentage ?
N/A
Market
Return 3 months ?
-20.3%
Return 6 months ?
-20.3%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 884444214311121 +3.6% -32.6%
Operating Profit -0000-1-000-1-0-0-0-0-1 -892.6% -107.7%
Other Income 10001000000000 -23.8% +14.3%
Interest 0000000000000— — —
Depreciation 0000000000000— — —
Profit Before Tax 00001001-1000-0-1 -273.7% -282.1%
Net Profit 00001001-1000-0-1 -273.7% -282.1%
EPS 0.000.000.000.000.010.010.010.02-0.020.010.000.010.00-0.01 -200.0% —
OPM % -6.0% 1.8% 1.9% 2.2% -13.8% -3.7% 1.0% 3.3% -47.2% -6.5% -51.9% -7.1% -20.3% -62.5% -861.5% -207.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹23 Cr ₹5 Cr ₹5 Cr -78.4%
Operating Profit ₹-1 Cr ₹-1 Cr ₹-2 Cr +8.5%
OPM % -4.62% -19.52% -35.33% -322.5%
NPM % 1.66% 10.26% -7.83% +518.1%
Other Income ₹1 Cr ₹1 Cr ₹1 Cr +2.8%
Depreciation ₹0 Cr ₹0 Cr ₹0 Cr —
Interest ₹0 Cr ₹0 Cr ₹0 Cr —
EBIT ₹-1 Cr ₹-1 Cr ₹-2 Cr +8.5%
PBT ₹0 Cr ₹1 Cr ₹-0 Cr +34.2%
Tax — — — —
Net Profit ₹0 Cr ₹1 Cr ₹-0 Cr +34.2%
EPS ₹0.02 ₹0.02 ₹0.00 +0.0%
Material Cost — — ₹2 Cr —
Employee Cost — — ₹0 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 39.8639.8639.8639.86 +0.0%
Reserves 22.4923.1223.3923.77 +1.6%
Borrowings 0.000.000.000.00 —
Other Liabilities 17.1810.640.240.17 -29.2%
Total Liabilities 79.5373.6263.4963.80 +0.5%
Fixed Assets 0.000.000.000.00 —
CWIP 0.000.000.000.00 —
Investments 0.000.009.159.15 +0.0%
Other Assets 79.5373.6254.3454.65 +0.6%
Total Assets 79.5373.6263.4963.80 +0.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 10.5410.16-10.21-8.20 +19.7%
Cash from Investing Activity -10.09-10.219.808.19 -16.4%
Cash from Financing Activity 0.000.000.000.00 —
Net Cash Flow 0.44-0.05-0.410.00 +100.0%
Free Cash Flow 10.5410.16-10.21-8.20 +19.7%
CFO/OP 522%-5,080%972%843% -13.3%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 112.9859.390.000.00 —
Inventory Days 0.000.0046.59846.14 +1716.1%
Days Payable ——0.000.00 —
Cash Conversion Cycle 112.9859.3946.59846.14 +1716.1%
Working Capital Days 12.80-132.1150.08860.72 +1618.7%
ROCE % 4.42%1.37%0.62%0.80% +29.0%

👥 Shareholding (latest 4 periods)

Metric Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
FIIs 1.42%1.42%1.42%1.42% +0.0%
Public 98.58%98.58%98.59%98.59% +0.0%
No. of Shareholders 1,89,3751,86,1481,83,6581,81,722 -1.1%

⚖️ Peer comparison

Industry: Biotechnology · 8 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 BIOCON Biocon ₹390.65 63,609 147.4 17,322 417 20.4% 2.4% 10.9% -74.2% 10.0% 53.4%
2 ANTHEM ANTHEM BIOSCIENCES ₹874.85 49,142 85.4 2,002 576 39.6% 28.8% — — -22.6% -11.7%
3 ONESOURCE ONESOURCE SPECL ₹1,592.00 18,256 — 1,544 -49 21.9% -3.2% -1.6% -185.0% 37.3% 0.7%
4 CONCORDBIO Concord Biotech ₹1,510.00 15,797 57.6 1,109 273 34.9% 24.6% -12.1% -30.4% 26.2% 31.0%
5 514336 CCME Global ₹15.10 150 — 0 -1 -2079.0% -2135.5% -98.9% -120.3% — -120.2%
6 511509 Vivo Bio ₹37.69 37 — 55 -3 37.0% -5.2% 14.3% -123.4% 14.1% -86.0%
7 539470 Shree Ganesh ₹1.20 18 — 5 -0 -35.3% -7.8% -78.4% 34.2% 3.6% -273.7%
8 539206 Genomic Valley ₹52.00 9 n/m 0 0 11.7% 6.7% -68.2% -94.4% -57.8% -26.9%
❓ Frequently asked questions
What was Shree Ganesh Biotech (India) Ltd's revenue in Q1 FY27?
Shree Ganesh Biotech (India) Ltd reported revenue of ₹1 crore for the quarter ended June 2026 (Q1 FY27), up 3.6% from ₹1 crore in the same quarter last year, and down 32.6% sequentially over the March 2026 quarter.
What was Shree Ganesh Biotech (India) Ltd's net profit in Q1 FY27?
The company reported a net loss of ₹1 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.01.
What is 539470's market capitalisation and P/E ratio?
At the current price of ₹0.47, 539470 has a market capitalisation of ₹18 crore.
Who owns Shree Ganesh Biotech (India) Ltd? (shareholding pattern)
As of Jun 2026, foreign institutional investors (FIIs) 1.42%, public shareholders 98.59% of Shree Ganesh Biotech (India) Ltd.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI